Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2022 | Benefits of a biomarker to predict sever toxicity

Michel Obeid • 4 Apr 2022
ELCC 2022
Lung Cancer

Michel Obeid, MD, PhD, CHUV – Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, discusses investigating a particular type of biomarker to predict and therefore avoid severe toxicity to ultimately improve a patients safety and tolerance to therapeutic agents. This interview took place during the virtual European Lung Cancer Congress 2022.

More from Michel Obeid

3:11
ImmunoVax: neutralizing responses in cancer patients and variants in regards to COVID19
Michel Obeid • 4 Apr 2022
1:08
Challenges in regards to adverse events when treating lung cancer with IO
Michel Obeid • 4 Apr 2022

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals